Stride Kai, Understanding GLP-1 Medications
Millions of people are currently on, have recently stopped, or are thinking about stopping GLP-1 medications like Ozempic and Wegovy. The question of what happens after is one of the most searched health topics of 2026, and the answers floating around are a mix of clinical data, anecdote, and anxiety.
Here's what the peer-reviewed research actually shows, week by week, and what it means practically.
First, a clear statement: stopping these medications is a personal medical decision that should always be made with your doctor. The data below is for information only.
To understand the timeline, it helps to understand the mechanism. GLP-1 medications work by mimicking a hormone your gut releases after eating. They slow stomach emptying, reduce appetite signals in the brain, and create a sustained feeling of fullness. The result is that you eat less, often significantly less, without consciously trying.
As researchers at the University of Cambridge described it: "Drugs such as Ozempic and Wegovy act like brakes on our appetite. When people stop taking them, they are essentially taking their foot off the brake."
When the drug leaves your system, those brakes release. Appetite returns. Hunger signals that were suppressed during treatment come back, sometimes with intensity. The body, which has been in a calorie deficit for months, begins actively trying to restore its energy reserves.
Semaglutide (Ozempic, Wegovy) has a half-life of approximately one week, meaning half the drug leaves your system in the first 7 days. During this period many people notice appetite beginning to return, particularly the return of between-meal hunger that the medication had suppressed. Energy levels may fluctuate as your body adjusts.
By weeks two to four, the appetite suppression that characterised your time on the medication has largely gone. This is the period researchers identify as the highest risk for rapid weight regain. A 2021 clinical trial found that adults who switched from Wegovy to a placebo after 20 weeks saw their weight begin increasing almost immediately. Hunger regulation, blood sugar patterns, and stomach emptying all begin returning to pre-treatment behaviour.
A 2026 BMJ analysis of 37 studies covering 9,300 people found that those who stopped GLP-1 medications regained weight approximately four times faster than people who had lost weight through diet and exercise alone. In the first few months, people taking the most common GLP-1 drugs averaged regaining 22 of the 33 pounds they had lost. Blood pressure readings, which had improved during treatment, begin returning toward pre-treatment levels in many patients.
There is genuinely hopeful news here. University of Cambridge research found that weight regain plateaus after about a year, with people managing to keep off around 25% of the weight they had lost during treatment. A 2022 clinical trial found patients retained a net 5% weight loss a year after stopping, which is clinically meaningful. The picture isn't total reversal. But it's significantly worse without an established exercise habit in place.
The BMJ analysis found that most people who stopped GLP-1 medications without establishing lifestyle changes returned to approximately their starting weight within 18 months. This isn't a universal outcome. But it is the most common one in the research data.
The research contains one finding that consistently separates the people who keep most of their results from those who don't. It isn't diet alone. It isn't willpower. It's whether a consistent exercise habit was built during treatment.
A 2024 clinical study found that people who exercised regularly while taking GLP-1 medications kept off significantly more weight after stopping than those who didn't. The ACSM confirmed this in their 2026 research report: individuals who maintained exercise during GLP-1 treatment saw higher fat loss retention and lean mass preservation after stopping medication than those who relied on the drug alone.
The mechanism makes sense. Exercise builds the metabolic infrastructure that the drug can't. It preserves muscle, which keeps your resting metabolism higher. It establishes the daily habit and identity that persists after the medication is gone. And it creates the physical adaptation, improved cardiovascular fitness, stronger legs, better blood pressure, that doesn't reverse simply because a prescription has ended.
When appetite is suppressed and calorie intake is reduced, intense exercise can feel genuinely difficult. The body has less fuel. High-intensity training during GLP-1 treatment risks fatigue, muscle breakdown, and burnout.
Walking is the exercise most consistently recommended by researchers and clinicians alongside GLP-1 therapy. It's low impact. It requires no recovery time. It can be done daily without overtaxing a body adjusting to significantly less food. And when structured with the right method, the interval walking protocol developed by Dr. Hiroshi Nose at Shinshu University in Japan, it produces cardiovascular and metabolic benefits that support the drug's goals and outlast them.
The key word is structured. Casual strolling produces modest benefits. Dr. Nose's alternating fast and slow walking protocol, 30 minutes of precisely timed intervals, produces the kind of cardiovascular adaptation and fat-burning response that your body carries with it long after any medication has cleared your system.
Stride Kai guides Dr. Nose's interval walking protocol with audio and vibration cues. Low impact enough to do daily, effective enough to build the metabolic foundation that keeps results after anything else changes. Free 3-day trial on the annual plan.
Research shows weight regain begins within the first few weeks of stopping, as the appetite-suppressing effects wear off over 7 to 14 days. The 2026 BMJ analysis found regain is approximately four times faster after stopping GLP-1 medications than after losing weight through diet and exercise alone. Most significant regain occurs in the first three to six months.
Yes, some. University of Cambridge research found people retained around 25% of their lost weight at 12 months. A 2022 clinical trial showed a net 5% body weight reduction persisted a year after stopping. People who had built consistent exercise habits during treatment retained significantly more than those who hadn't.
Not inevitable, but common. The 2026 Cleveland Clinic study of nearly 8,000 patients found a more varied picture than earlier clinical trials: many people managed to maintain results by restarting treatment, switching medications, or adopting genuine lifestyle changes. The outcome is significantly better when exercise habits are established during treatment rather than after stopping.
Research consistently points to three factors: continued dietary awareness, regular exercise built during treatment rather than started after stopping, and in many cases restarting or switching medications. Of these, exercise is the factor most within a person's control and the one with the most consistent evidence base for preserving results.
Sources: British Medical Journal analysis (January 2026), University of Cambridge research (2026), eClinicalMedicine systematic review (2026), Scientific American / JAMA Network Open analysis (2026), Medical News Today semaglutide clinical review (2026), ACSM Top Fitness Trends Report (2026). This article is informational only and does not constitute medical advice.
Related reading: Ozempic and exercise, what the research says about working out during treatment · The Japanese walking method, the 30-minute protocol recommended alongside GLP-1 therapy